Comments
Zydus Cadila (Cadila Healthcare) has received final approval from the USFDA to market Leflunomide tablets USP (US RLD - Arava Tablets), 10 mg and 20 mg. The drugs will be manufactured at its formulations manufacturing facility at Baddi. This medication is used to treat rheumatoid arthritis. The group now has 263 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04. Shareholders will watch further developments.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.